Is HER2 overexpression sufficient for optimal response to Pertuzumab?

被引：0
作者：
Sendur, Mehmet Ali Nahit [1 ]
Aksoy, Sercan [1 ]
Yaman, Sebnem [1 ]
Ozdemir, Nuriye Yildirim [1 ]
Zengin, Nurullah [1 ]
机构：
[1] Ankara Numune Training & Res Hosp, Dept Med Oncol, TR-06100 Ankara, Turkey
来源：
MEDICAL ONCOLOGY | 2012年 / 29卷 / 04期
关键词：
METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; PLUS; TRASTUZUMAB; RECEPTOR;
D O I：
10.1007/s12032-012-0183-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2565 / 2566
页数：2
相关论文
共 9 条
[1]   Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab [J].
Adams, CW ;
Allison, DE ;
Flagella, K ;
Presta, L ;
Clarke, J ;
Dybdal, N ;
McKeever, K ;
Sliwkowski, MX .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :717-727
[2]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[3]   HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival A Study of 4046 Patients [J].
Chiu, Connie G. ;
Masoudi, Hamid ;
Leung, Samuel ;
Voduc, David K. ;
Gilks, Blake ;
Huntsman, David G. ;
Wiseman, Sam M. .
ANNALS OF SURGERY, 2010, 251 (06) :1107-1116
[4]   Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J].
Gianni, Luca ;
Pienkowski, Tadeusz ;
Im, Young-Hyuck ;
Roman, Laslo ;
Tseng, Ling-Ming ;
Liu, Mei-Ching ;
Lluch, Ana ;
Staroslawska, Elzbieta ;
de la Haba-Rodriguez, Juan ;
Im, Seock-Ah ;
Pedrini, Jose Luiz ;
Poirier, Brigitte ;
Morandi, Paolo ;
Semiglazov, Vladimir ;
Srimuninnimit, Vichien ;
Bianchi, Giulia ;
Szado, Tania ;
Ratnayake, Jayantha ;
Ross, Graham ;
Valagussa, Pinuccia .
LANCET ONCOLOGY, 2012, 13 (01) :25-32
[5]   Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [J].
Makhija, Sharmila ;
Amler, Lukas C. ;
Glenn, Dana ;
Ueland, Frederick R. ;
Gold, Michael A. ;
Dizon, Don S. ;
Paton, Virginia ;
Lin, Chin-Yu ;
Januario, Thomas ;
Ng, Kimmie ;
Strauss, Andreas ;
Kelsey, Stephen ;
Sliwkowski, Mark X. ;
Matulonis, Ursula .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1215-1223
[6]   The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells [J].
Naresh, Anjali ;
Long, Weiwen ;
Vidal, Gregory A. ;
Wimley, William C. ;
Marrero, Luis ;
Sartor, Carolyn I. ;
Tovey, Sian ;
Cooke, Timothy G. ;
Bartlett, John M. S. ;
Jones, Frank E. .
CANCER RESEARCH, 2006, 66 (12) :6412-6420
[7]   The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine (Publication with Expression of Concern) [J].
Ross, Jeffrey S. ;
Slodkowska, Elzbieta A. ;
Symmans, W. Fraser ;
Pusztai, Lajos ;
Ravdin, Peter M. ;
Hortobagyi, Gabriel N. .
ONCOLOGIST, 2009, 14 (04) :320-368
[8]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
[9]   Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling [J].
Tovey, SM ;
Witton, CJ ;
Bartlett, JMS ;
Stanton, PD ;
Reeves, JR ;
Cooke, TG .
BREAST CANCER RESEARCH, 2004, 6 (03) :R246-R251
1